Skip to main content
. Author manuscript; available in PMC: 2019 Apr 9.
Published in final edited form as: Cancer Discov. 2017 Sep 18;8(1):74–93. doi: 10.1158/2159-8290.CD-17-0682

Figure 7.

Figure 7

Strategies to select against MAPKi-resistant melanoma. Schematic showing MAPKi-addiction phenotypes being driven by p-ERK rebound levels and potential therapeutic strategies (enhancing p-ERK or impairing DNA damage repair) that promote tumor cell-death (apoptosis or parthanatos) or regression.